Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/25765
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAndrew J.H. Simpsonen_US
dc.contributor.authorYupin Suputtamongkolen_US
dc.contributor.authorMichael D. Smithen_US
dc.contributor.authorBrian J. Angusen_US
dc.contributor.authorAdul Rajanuwongen_US
dc.contributor.authorVanaporn Wuthiekanunen_US
dc.contributor.authorPaul A. Hoween_US
dc.contributor.authorAmanda L. Walshen_US
dc.contributor.authorWipada Chaowagulen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherSappasitthiprasong Hospitalen_US
dc.contributor.otherCentre for Tropical Medicineen_US
dc.contributor.otherJohn Radcliffe Hospitalen_US
dc.contributor.otherMusgrove Park Hospitalen_US
dc.contributor.otherMalaria Proj./Wellcome Trust Res. L.en_US
dc.date.accessioned2018-09-07T09:01:42Z-
dc.date.available2018-09-07T09:01:42Z-
dc.date.issued1999-01-01en_US
dc.identifier.citationClinical Infectious Diseases. Vol.29, No.2 (1999), 381-387en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-0032777243en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0032777243&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/25765-
dc.description.abstractAn open, prospective, randomized, comparative treatment trial was conducted to compare the therapeutic efficacy of high-dose intravenous imipenem and ceftazidime for acute severe melioidosis. Adult Thai patients with suspected acute, severe melioidosis were randomized to receive either imipenem, at a dosage of 50 mg/(kg · d), or ceftazidime, at a dosage of 120 mg/(kg · d), for a minimum of 10 days. The main outcome measures were death or treatment failure. Of the 296 patients enrolled, 214 had culture-confirmed melioidosis, and 132 (61.7%) of them had positive blood cultures. Mortality among patients with melioidosis was 36,9% overall. There were no differences in survival overall (P = .96) or after 48 hours (P = .3). Treatment failure after 48 hours was more common among patients treated with ceftazidime (P = .011). Both treatments were well tolerated. Imipenem is a safe and effective treatment for acute severe melioidosis and may be considered an alternative to ceftazidime.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0032777243&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleComparison of imipenem and ceftazidime as therapy for severe melioidosisen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1086/520219en_US
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.